Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It also provides clinical development services to the biotechnology, pharmaceutical, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
IPO Year: 2016
Exchange: NASDAQ
Website: medpace.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/23/2024 | $413.00 → $349.00 | Outperform → Neutral | Robert W. Baird |
| 10/14/2024 | Buy | Redburn Atlantic | |
| 9/27/2024 | $420.00 → $350.00 | Buy → Neutral | UBS |
| 9/25/2024 | $415.00 → $345.00 | Buy → Hold | Jefferies |
| 8/1/2024 | $415.00 | Hold | Truist |
| 5/29/2024 | $452.00 | Buy | TD Cowen |
| 5/28/2024 | $435.00 | Buy | Mizuho |
| 4/23/2024 | $340.00 → $450.00 | Hold → Buy | Jefferies |
| 3/18/2024 | $395.00 | Hold | Deutsche Bank |
| 2/15/2024 | $282.00 → $452.00 | Neutral → Buy | UBS |
Appointment of Jesse Geiger as President and Kevin Brady as Chief Financial Officer Medpace Holdings, Inc. (NASDAQ:MEDP) ("Medpace") today announced the appointment of Jesse Geiger as president and Kevin Brady as chief financial officer, effective August 1, 2021. August Troendle will continue to serve as Medpace's chairman and chief executive officer. Geiger joined Medpace in 2007 as corporate controller and became chief financial officer in 2011. In 2014, Geiger expanded his role to include chief operating officer of laboratory operations. Geiger will continue to report to August Troendle. The newly created position of president will allow Troendle to continue to focus on the overall lon
10-Q - Medpace Holdings, Inc. (0001668397) (Filer)
8-K - Medpace Holdings, Inc. (0001668397) (Filer)
144/A - Medpace Holdings, Inc. (0001668397) (Subject)
144 - Medpace Holdings, Inc. (0001668397) (Subject)
10-Q - Medpace Holdings, Inc. (0001668397) (Filer)
8-K - Medpace Holdings, Inc. (0001668397) (Filer)
8-K - Medpace Holdings, Inc. (0001668397) (Filer)
8-K - Medpace Holdings, Inc. (0001668397) (Filer)
144 - Medpace Holdings, Inc. (0001668397) (Subject)
10-Q - Medpace Holdings, Inc. (0001668397) (Filer)
Robert W. Baird downgraded Medpace from Outperform to Neutral and set a new price target of $349.00 from $413.00 previously
Redburn Atlantic initiated coverage of Medpace with a rating of Buy
UBS downgraded Medpace from Buy to Neutral and set a new price target of $350.00 from $420.00 previously
Jefferies downgraded Medpace from Buy to Hold and set a new price target of $345.00 from $415.00 previously
Truist initiated coverage of Medpace with a rating of Hold and set a new price target of $415.00
TD Cowen initiated coverage of Medpace with a rating of Buy and set a new price target of $452.00
Mizuho initiated coverage of Medpace with a rating of Buy and set a new price target of $435.00
Jefferies upgraded Medpace from Hold to Buy and set a new price target of $450.00 from $340.00 previously
Deutsche Bank initiated coverage of Medpace with a rating of Hold and set a new price target of $395.00
UBS upgraded Medpace from Neutral to Buy and set a new price target of $452.00 from $282.00 previously
4 - Medpace Holdings, Inc. (0001668397) (Issuer)
4 - Medpace Holdings, Inc. (0001668397) (Issuer)
4 - Medpace Holdings, Inc. (0001668397) (Issuer)
4 - Medpace Holdings, Inc. (0001668397) (Issuer)
4 - Medpace Holdings, Inc. (0001668397) (Issuer)
4 - Medpace Holdings, Inc. (0001668397) (Issuer)
4 - Medpace Holdings, Inc. (0001668397) (Issuer)
4 - Medpace Holdings, Inc. (0001668397) (Issuer)
4 - Medpace Holdings, Inc. (0001668397) (Issuer)
4 - Medpace Holdings, Inc. (0001668397) (Issuer)
Medpace Holdings, Inc. (NASDAQ:MEDP) ("Medpace") today announced that it will report its fourth quarter and fiscal year 2024 financial results after the market close on Monday, February 10, 2025. The Company will host a conference call the following morning, Tuesday, February 11, 2025, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a uniq
Revenue of $533.3 million in the third quarter of 2024 increased 8.3% from revenue of $492.5 million for the comparable prior-year period, representing a backlog conversion rate of 18.2%. Net new business awards were $533.7 million in the third quarter of 2024, representing a decrease of 12.7% from net new business awards of $611.5 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 1.00x. Third quarter of 2024 GAAP net income was $96.4 million, or $3.01 per diluted share, versus GAAP net income of $70.6 million, or $2.22 per diluted share, for the comparable prior-year period. Net income margin was 18.1% and 14.3% for the third quarter of 2024 a
Medpace Holdings, Inc. (NASDAQ:MEDP) ("Medpace") today announced that it will report its third quarter 2024 financial results after the market close on Monday, October 21, 2024. The Company will host a conference call the following morning, Tuesday, October 22, 2024, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique PIN that can be u
CHARLOTTE, N.C., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Glatfelter Corporation (NYSE:GLT), and Berry Global Group, Inc. (NYSE:BERY) today announce additional director designees for the board of directors for the combined company. The new directors will be appointed and will begin serving as directors effective upon the closing of the proposed merger of Berry's Health, Hygiene and Specialties Global Nonwovens and Films ("HHNF") business with Glatfelter. As previously disclosed, upon closing of the transaction, the combined company will be renamed Magnera Corporation ("Magnera"). The Magnera board of directors ("Magnera Board") will consist of nine directors, with five directors designated by Be
Revenue of $528.1 million in the second quarter of 2024 increased 14.6% from revenue of $460.9 million for the comparable prior-year period, representing a backlog conversion rate of 18.2%. Net new business awards were $551.0 million in the second quarter of 2024, representing a decrease of 4.1% from net new business awards of $574.8 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 1.04x. Second quarter of 2024 GAAP net income was $88.4 million, or $2.75 per diluted share, versus GAAP net income of $61.1 million, or $1.93 per diluted share, for the comparable prior-year period. Net income margin was 16.7% and 13.3% for the second quarter of
Medpace Holdings, Inc. (NASDAQ:MEDP) ("Medpace") today announced that it will report its second quarter 2024 financial results after the market close on Monday, July 22, 2024. The Company will host a conference call the following morning, Tuesday, July 23, 2024, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique PIN that can be used
Revenue of $511.0 million in the first quarter of 2024 increased 17.7% from revenue of $434.1 million for the comparable prior-year period, representing a backlog conversion rate of 18.2%. Net new business awards were $615.6 million in the first quarter of 2024, representing an increase of 10.8% from net new business awards of $555.8 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 1.20x. First quarter of 2024 GAAP net income was $102.6 million, or $3.20 per diluted share, versus GAAP net income of $72.9 million, or $2.27 per diluted share, for the comparable prior-year period. Net income margin was 20.1% and 16.8% for the first quarter of 2
Medpace Holdings, Inc. (NASDAQ:MEDP) ("Medpace") today announced that it will report its first quarter 2024 financial results after the market close on Monday, April 22, 2024. The Company will host a conference call the following morning, Tuesday, April 23, 2024, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique PIN that can be used
Revenue of $498.4 million in the fourth quarter of 2023 increased 26.5% from revenue of $394.1 million for the comparable prior-year period, representing a backlog conversion rate of 18.5%. Net new business awards were $614.7 million in the fourth quarter of 2023, representing an increase of 26.7% from net new business awards of $485.1 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 1.23x. Fourth quarter of 2023 GAAP net income was $78.3 million, or $2.46 per diluted share, versus GAAP net income of $68.7 million, or $2.12 per diluted share, for the comparable prior-year period. Net income margin was 15.7% and 17.4% for the fourth quarter o
Medpace Holdings, Inc. (NASDAQ:MEDP) ("Medpace") today announced that it will report its fourth quarter and fiscal year 2023 financial results after the market close on Monday, February 12, 2024. The Company will host a conference call the following morning, Tuesday, February 13, 2024, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a uniq
Medpace Holdings, Inc. (NASDAQ:MEDP) ("Medpace") today announced that it will report its fourth quarter and fiscal year 2024 financial results after the market close on Monday, February 10, 2025. The Company will host a conference call the following morning, Tuesday, February 11, 2025, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a uniq
Revenue of $533.3 million in the third quarter of 2024 increased 8.3% from revenue of $492.5 million for the comparable prior-year period, representing a backlog conversion rate of 18.2%. Net new business awards were $533.7 million in the third quarter of 2024, representing a decrease of 12.7% from net new business awards of $611.5 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 1.00x. Third quarter of 2024 GAAP net income was $96.4 million, or $3.01 per diluted share, versus GAAP net income of $70.6 million, or $2.22 per diluted share, for the comparable prior-year period. Net income margin was 18.1% and 14.3% for the third quarter of 2024 a
Medpace Holdings, Inc. (NASDAQ:MEDP) ("Medpace") today announced that it will report its third quarter 2024 financial results after the market close on Monday, October 21, 2024. The Company will host a conference call the following morning, Tuesday, October 22, 2024, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique PIN that can be u
Revenue of $528.1 million in the second quarter of 2024 increased 14.6% from revenue of $460.9 million for the comparable prior-year period, representing a backlog conversion rate of 18.2%. Net new business awards were $551.0 million in the second quarter of 2024, representing a decrease of 4.1% from net new business awards of $574.8 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 1.04x. Second quarter of 2024 GAAP net income was $88.4 million, or $2.75 per diluted share, versus GAAP net income of $61.1 million, or $1.93 per diluted share, for the comparable prior-year period. Net income margin was 16.7% and 13.3% for the second quarter of
Medpace Holdings, Inc. (NASDAQ:MEDP) ("Medpace") today announced that it will report its second quarter 2024 financial results after the market close on Monday, July 22, 2024. The Company will host a conference call the following morning, Tuesday, July 23, 2024, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique PIN that can be used
Revenue of $511.0 million in the first quarter of 2024 increased 17.7% from revenue of $434.1 million for the comparable prior-year period, representing a backlog conversion rate of 18.2%. Net new business awards were $615.6 million in the first quarter of 2024, representing an increase of 10.8% from net new business awards of $555.8 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 1.20x. First quarter of 2024 GAAP net income was $102.6 million, or $3.20 per diluted share, versus GAAP net income of $72.9 million, or $2.27 per diluted share, for the comparable prior-year period. Net income margin was 20.1% and 16.8% for the first quarter of 2
Medpace Holdings, Inc. (NASDAQ:MEDP) ("Medpace") today announced that it will report its first quarter 2024 financial results after the market close on Monday, April 22, 2024. The Company will host a conference call the following morning, Tuesday, April 23, 2024, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique PIN that can be used
Revenue of $498.4 million in the fourth quarter of 2023 increased 26.5% from revenue of $394.1 million for the comparable prior-year period, representing a backlog conversion rate of 18.5%. Net new business awards were $614.7 million in the fourth quarter of 2023, representing an increase of 26.7% from net new business awards of $485.1 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 1.23x. Fourth quarter of 2023 GAAP net income was $78.3 million, or $2.46 per diluted share, versus GAAP net income of $68.7 million, or $2.12 per diluted share, for the comparable prior-year period. Net income margin was 15.7% and 17.4% for the fourth quarter o
Medpace Holdings, Inc. (NASDAQ:MEDP) ("Medpace") today announced that it will report its fourth quarter and fiscal year 2023 financial results after the market close on Monday, February 12, 2024. The Company will host a conference call the following morning, Tuesday, February 13, 2024, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a uniq
Revenue of $492.5 million in the third quarter of 2023 increased 28.3% from revenue of $383.7 million for the comparable prior-year period, representing a backlog conversion rate of 19.1%. Net new business awards were $611.5 million in the third quarter of 2023, representing an increase of 29.9% from net new business awards of $470.9 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 1.24x. Third quarter of 2023 GAAP net income was $70.6 million, or $2.22 per diluted share, versus GAAP net income of $66.0 million, or $2.05 per diluted share, for the comparable prior-year period. Net income margin was 14.3% and 17.2% for the third quarter of 20
SC 13D/A - Medpace Holdings, Inc. (0001668397) (Subject)
SC 13D/A - Medpace Holdings, Inc. (0001668397) (Subject)
SC 13G/A - Medpace Holdings, Inc. (0001668397) (Subject)
SC 13G/A - Medpace Holdings, Inc. (0001668397) (Subject)
SC 13G/A - Medpace Holdings, Inc. (0001668397) (Subject)
SC 13D/A - Medpace Holdings, Inc. (0001668397) (Subject)
SC 13D/A - Medpace Holdings, Inc. (0001668397) (Subject)
SC 13G/A - Medpace Holdings, Inc. (0001668397) (Subject)
SC 13G/A - Medpace Holdings, Inc. (0001668397) (Subject)
SC 13G/A - Medpace Holdings, Inc. (0001668397) (Subject)